-
China colorectal cancer tumor standardization diagnosis and treatment platform released.
Time of Update: 2020-08-16
Lin Lin, CEO of Anwant Smart Medical, said that the platform takes colorectal cancer as the starting point, mainly includes standardized diagnosis, standardized treatment, intelligent clinical assistance decision-making, tumor patients 360 degree view four parts, to provide clinical aids as the core value, through full-structured form, medical advice normative examination reminders, treatment plan recommendations, etc., to remind, intercept and avoid the occurrence of non-standardized diagnosis and treatment behavior.
-
Focus on the clinical frontiers of cancer! The 2019 China Cancer Congress was held.
Time of Update: 2020-08-16
(Health Times reporter Xu Wei) malignant tumor has become the number one threat to the health of our people, is currently China's largest public health problem. June 27-30, sponsored by the Chinese Me
-
Accurately remove tiny tumors! Fudan University has made important progress together.
Time of Update: 2020-08-16
experimental group modeled on mice in situ colon cancer microtumor, the albumin-near-infrared area of small molecule diagnosis and treatment preparation can achieve 0.5 mm x 0.3 mm micro-metastatic tumor in the operation of clear fluorescence imaging, and not subject to intestinal content fluorescence interference; This study opens up new research ideas and methods for the clinical transformation of the technology of real-time detection and photothermal removal of microtumors in surgery.
-
Can anti-tumor drugs be over-cooked? Guangdong's official guidance has come.
Time of Update: 2020-08-16
the drug specification is after a rigorous clinical trial, and is the drug supervision and administration department of the approval of the drug, has an important legal basis for the use of drugs, the Chinese Academy of Medical Sciences Oncology Hospital, deputy director of oncology medicine physician Liu Peng told the Health Times.
-
Xu Zhongfa: Early diagnosis and treatment can improve the survival rate of all tumors!
Time of Update: 2020-08-16
Xu Zhongfa, head of the early diagnosis and early treatment group of the Oncology Branch of the Chinese Medical Association , early prevention and treatment means that the early stage of malignant tumor can be diagnosed and necessary treatment and intervention in the early stage and even before the tumor, in order to reduce the overall incidence of tumors and improve the overall cure rate.
-
Five cancers are treated! Pfizer's cancer biosimilar sisenic siseine has been approved by the FDA.
Time of Update: 2020-08-16
ZIRABEV is a biosimilar to bevele monotoma, which has been approved for treatment of five types of cancer: metastatic colorectal cancer; non-removable local late, recurrent or metastatic non-scaly non-small cell lung cancer (NSCLC); recurrent glioblastoma; metastatic renal cell cancer (RCC) and persistent, recurrent or metastatic cervical cancer.
-
Five academicians talk about tumor prevention and control! The frontier breakthrough and the progress are here.
Time of Update: 2020-08-16
"First mark the pancreatic tumor, like a radar sweep, set the scope, and then put some radiation through an ultrasound endoscope through a special pathway in the tumor for close-range radiation therapy." "surgery plus", the most preferred treatment of liver cancer Chinese Academy of Engineering, Tsinghua Changxuan Hospital Executive Director Dong Jiahong primary liver cancer is one of the most common and malignant tumors, in the world, each year, there are more than 841,000 new cases of liver cancer.
-
Upgraded PD-1! Merck's dual-function tumor immunotherapy in Germany has been approved for clinical practice.
Time of Update: 2020-08-16
Merck KGaA has been granted implicit approval for clinical trials of new anti-tumor drugs (code m7824) for the treatment of non-small cell lung cancer (NSCLC), according to the latest announcement from the Drug Review Center (CDE) of the National Drug Administration.
-
The gospel of lung cancer patients! Lilly's classic anti-tumor drug, Lithane, is 30% lower than that of
Time of Update: 2020-08-16
Registered clinical JMIL in China and the world-renowned JMDB and PARAMOUNT clinical studies have shown that Libita's first-line and continuing treatment significantly prolongs the total survival of non-scale cancer patients.
doi: 10.1093/annonc/mdq189 3: Libita ® approved for advanced non-squamous non-small cell lung cancer and continue to be treated.
-
The first physical practice guide for stereotactic radiation therapy of chinese tumors has been published.
Time of Update: 2020-08-14
Professor Yu Jinming, a member of the Chinese Academy of Engineering and director of Shandong Cancer Hospital, stressed that the medical physics team plays a vital role in safeguarding the clinical work of radiation therapy, especially stereotactic radiosurgery.
-
Eteng Pharmaceuticals completed the B-round financing funds will be used to develop cancer research and development pipeline.
Time of Update: 2020-08-14
The funds from this round of financing will be used to further develop the EOC's mid- and late-stage clinical product pipeline and introduce more late-stage oncology product projects in order to bring newer and better treatment options to Chinese patients.
-
The country's first anti-tumor new drug MDM2-p53 inhibitors entered the clinic.
Time of Update: 2020-08-14
The design and development of new anti-tumor drugs with MDM2-p53 as the target is one of the hot spots and priorities in the field of global cancer drug research and development.
-
Heavy! National cancer, cardiovascular disease and other medical and therapeutic status published.
Time of Update: 2020-08-14
Recently, the National Health And Health Committee held a press conference, the Chinese Academy of Sciences, the National Center for Cancer Professional Quality Control Center, the National Cancer Cen
-
Will a long blister under your child's tongue be a tumor?
Time of Update: 2020-08-14
the treatment of pre-tongue cysts mainly to surgical treatment, surgery can not only remove cysts, but also to remove the deep glands, so that the operation is not easy to relapse.
-
Each year, 40,000 new, China's first brain tumor registration research platform line.
Time of Update: 2020-08-14
the establishment of the national brain tumor registration research platform will gradually include the Capital Medical University affiliated Beijing Tiantan Hospital, Peking University First Hospital, Capital Medical University Sanbo Brain Hospital and other 23 provinces, municipalities and autonomous regions of the country 43 different levels of hospital clinical data, the future will be China's first brain tumor professional clinical research public service platform, based on brain tumor "big data" large-scale, multi-center, high-quality diagnosis and treatment outcome research and clinical norms.
-
Pfizer has authorized the development of a new Drug for AKL-1 Target Tumor Antibodies.
Time of Update: 2020-08-14
agreement, Pfizer will grant the rights of the ALK-1 program to the global ization of research and development, production and commercialization to pioneer pharmaceutical companies and provide support for completed preclinical, Phase I clinical studies and know-how.
-
Reality version Zhao Dehan! The director of a department at Tianjin Cancer Hospital has been suspended for hiding cigarettes in his refrigerator.
Time of Update: 2020-08-14
doctor received gifts from patients suspended in response to this matter, reporters from Tianjin Medical University Cancer Hospital official website learned that On May 13 at 2 p.m., Tianjin Medical University Cancer Hospital held an emergency meeting of the whole hospital, the jaw otolaryngology oncology department director Wang Xudong illegal acceptance of patient gifts treatment decision to inform.
-
U.S. scientists have developed "gene test paper" to detect virus and tumor DNA.
Time of Update: 2020-08-14
Zhang Feng, a Chinese-American expert at the Broad Institute in the United States, has developed a "gene test paper" that successfully detects tumor markers in some patients with viral and lung cancer in the laboratory.
-
Peripheral vascular intervention and tumor minimally invasive intervention special capacity training project started.
Time of Update: 2020-08-14
In response to this situation, the National Health and Family Planning Commission Capacity Building and Continuing Education Center has launched a special capacity training project for intervention, which is based on improving the capacity of primary medical institutions to treat clinical treatment services for minimally invasive interventions, and ultimately effectively promotes graded diagnosis and treatment.
-
Tumor Dacu Beijing theory to jointly explore the new development of MDT in China.
Time of Update: 2020-08-14
(Health Times reporter Dong Lanjun) May 18, by the Chinese Physicians Association (CMDA) and Sanofi co-organized the 3rd MDT China Model Summit Forum held in Beijing. Vice President of Peking Univers